Targeting dendritic cells in lymph node with an antigen peptide-based nanovaccine for cancer immunotherapy.

The design of peptide-based subunit vaccine formulations for the direct delivery of tumor antigen peptides (Aps) to dendritic cells (DCs) localized within draining lymph nodes (DLNs) is challenging. Mature DCs (mDCs) are abundantly distributed within DLNs but have dramatically reduced endocytic uptake and antigen-processing abilities, so their role as potential vaccine targets has been largely overlooked. Here we report an ultra-small biocompatible nanovaccine (α-Ap-FNP) functionalized by avidly targeting delivery of Ap via the scavenger receptor class B1 (SR-B1) pathway to mDCs. The self-assembly, small size (∼30 nm), SR-B1-targeting and optical properties of α-Ap-FNP resulted in its efficient Ap loading, substantial LN accumulation, targeting of mDCs and enhanced Ap presentation, and fluorescence trafficking, respectively. We also demonstrate that the α-Ap-FNP can be either used alone or encapsulated with CpG oligodeoxynucleotide as a prophylactic and therapeutic vaccine. Thus, the excellent properties of α-Ap-FNP provide it potential for clinical applications as a potent nanovaccine for cancer immunotherapy.

[1]  Qingming Luo,et al.  HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. , 2010, Small.

[2]  James McCluskey,et al.  More than one reason to rethink the use of peptides in vaccine design , 2007, Nature Reviews Drug Discovery.

[3]  Dong Wang,et al.  Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma. , 2015, ACS nano.

[4]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[5]  C. Reis e Sousa.  Dendritic cells in a mature age , 2006, Nature reviews. Immunology.

[6]  K. Kang,et al.  Near-infrared emitting polymer nanogels for efficient sentinel lymph node mapping. , 2012, ACS nano.

[7]  Xiaoquan Yang,et al.  Molecular imaging of small animals with fluorescent proteins: From projection to multimodality , 2012, Comput. Medical Imaging Graph..

[8]  Michel C. Nussenzweig,et al.  Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance , 2002, The Journal of experimental medicine.

[9]  Rui Tian,et al.  Virus-mimetic nanovesicles as a versatile antigen-delivery system , 2015, Proceedings of the National Academy of Sciences.

[10]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[11]  Yasunobu Miyake,et al.  CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. , 2011, Immunity.

[12]  J. Hubbell,et al.  Synthesis of pyridyl disulfide-functionalized nanoparticles for conjugating thiol-containing small molecules, peptides, and proteins. , 2010, Bioconjugate chemistry.

[13]  M. Skwarczynski,et al.  Peptide-based subunit nanovaccines. , 2011, Current drug delivery.

[14]  C. Mandl,et al.  Vaccines for the twenty-first century society , 2012, Nature Reviews Immunology.

[15]  Gerold Schuler,et al.  Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? , 2002, Trends in immunology.

[16]  J. Hubbell,et al.  Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes , 2014, Cancer Immunology Research.

[17]  Zhihong Zhang,et al.  Efficient systemic delivery of siRNA by using high-density lipoprotein-mimicking peptide lipid nanoparticles. , 2012, Nanomedicine.

[18]  C. Figdor,et al.  Targeting dendritic cells--why bother? , 2013, Blood.

[19]  Qingming Luo,et al.  Biomimetic nanocarrier for direct cytosolic drug delivery. , 2009, Angewandte Chemie.

[20]  R. Steinman,et al.  The CD8+ Dendritic Cell Subset Selectively Endocytoses Dying Cells in Culture and In Vivo , 2002, The Journal of experimental medicine.

[21]  I. Melero,et al.  Therapeutic vaccines for cancer: an overview of clinical trials , 2014, Nature Reviews Clinical Oncology.

[22]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[23]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[24]  R. Förster,et al.  Lymph node homing of T cells and dendritic cells via afferent lymphatics. , 2012, Trends in immunology.

[25]  C Danieli,et al.  Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products , 1995, The Journal of experimental medicine.

[26]  I. Mellman,et al.  Mature dendritic cells use endocytic receptors to capture and present antigens , 2010, Proceedings of the National Academy of Sciences.

[27]  Michael S. Goldberg,et al.  Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy , 2015, Cell.

[28]  R. Langer,et al.  Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. , 2010, Nanomedicine.

[29]  H. R. Hendricks,et al.  Lymph Node Macrophages , 1980 .

[30]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[31]  Gang Zheng,et al.  Imaging the Cytosolic Drug Delivery Mechanism of HDL-Like Nanoparticles , 2013, Pharmaceutical Research.

[32]  Gregory L. Szeto,et al.  Structure-based programming of lymph-node targeting in molecular vaccines , 2014, Nature.

[33]  R. Steinman,et al.  In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.

[34]  Ying Zheng,et al.  ESTABLISHMENT OF VISIBLE ANIMAL METASTASIS MODELS FOR HUMAN NASOPHARYNGEAL CARCINOMA BASED ON A FAR-RED FLUORESCENT PROTEIN , 2012 .

[35]  V. Apostolopoulos,et al.  Targeting Antigens to Dendritic Cell Receptors for Vaccine Development , 2013, Journal of drug delivery.

[36]  S. Neelamegham,et al.  Functionalization of Cobalt Porphyrin-Phospholipid Bilayers with His-tagged Ligands and Antigens , 2015, Nature chemistry.

[37]  K. Ahn,et al.  Simultaneous in vivo tracking of dendritic cells and priming of an antigen-specific immune response. , 2011, Biomaterials.

[38]  Wah Chiu,et al.  Interbilayer-Crosslinked Multilamellar Vesicles as Synthetic Vaccines for Potent Humoral and Cellular Immune Responses , 2011, Nature materials.

[39]  E. Susaki,et al.  Whole-Brain Imaging with Single-Cell Resolution Using Chemical Cocktails and Computational Analysis , 2014, Cell.

[40]  J. Banchereau,et al.  Dendritic-cell-based therapeutic cancer vaccines. , 2013, Immunity.

[41]  C. Benoist,et al.  The Dendritic Cell Populations of Mouse Lymph Nodes1 , 2001, The Journal of Immunology.

[42]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[43]  C. Figdor,et al.  Perspectives Targeting dendritic cells — why bother ? , 2013 .

[44]  J. Villadangos,et al.  Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. , 2006, Immunity.

[45]  Young Keun Kim,et al.  A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. , 2011, Nature nanotechnology.

[46]  Wei R. Chen,et al.  Photonics immunotherapy-A novel strategy for cancer treatment , 2016 .

[47]  Yang Yang,et al.  Nanoparticle-based immunotherapy for cancer. , 2015, ACS nano.

[48]  T. Kündig,et al.  Lympho-geographical concepts in vaccine delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[49]  L. Raez,et al.  Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. , 2010, Seminars in immunology.

[50]  E. Trombetta,et al.  Dendritic Cells Continue To Capture and Present Antigens after Maturation In Vivo , 2010, The Journal of Immunology.

[51]  Mark J. Miller,et al.  Two-Photon Imaging of Lymphocyte Motility and Antigen Response in Intact Lymph Node , 2002, Science.

[52]  Yixin Zeng,et al.  Scavenger Receptor B1 is a Potential Biomarker of Human Nasopharyngeal Carcinoma and Its Growth is Inhibited by HDL-mimetic Nanoparticles , 2013, Theranostics.

[53]  G. Mazzolini,et al.  [Dendritic cell-based therapeutic cancer vaccines]. , 2016, Medicina.

[54]  Ying Zheng,et al.  VISUALIZATION OF HEAD AND NECK CANCER MODELS WITH A TRIPLE FUSION REPORTER GENE , 2012 .

[55]  Gang Zheng,et al.  Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model. , 2014, Small.

[56]  Enhancing Ef fi cacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes , 2014 .

[57]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[58]  V. Apostolopoulos,et al.  Receptor-mediated delivery of antigens to dendritic cells: anticancer applications. , 2007, Molecular pharmaceutics.

[59]  D. Irvine,et al.  Particulate vaccines: on the quest for optimal delivery and immune response. , 2011, Drug discovery today.

[60]  B. Rouse,et al.  Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study. , 1992, Cancer research.

[61]  J. Neefjes,et al.  Towards a systems understanding of MHC class I and MHC class II antigen presentation , 2011, Nature Reviews Immunology.

[62]  Daejin Kim,et al.  Imageable antigen-presenting gold nanoparticle vaccines for effective cancer immunotherapy in vivo. , 2012, Angewandte Chemie.